Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 7/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557009 | 1.00 | LTB4R (0.34) | LTB4RLTB4R2ESR1KMT2ACYP11B1 | |
| SCHEMBL557841 | 0.79 | NR4A1 (0.43) | CYP11B1CYP11B2NR4A1NR4A2NR4A3 | |
| SCHEMBL557077 | 0.76 | NR4A1 (0.51) | LTB4RLTB4R2ESR1NR4A1NR4A2 | |
| SCHEMBL556415 | 0.76 | CA1 (0.41) | LTB4RLTB4R2KMT2AHPGDMEN1 | |
| SCHEMBL556416 | 0.76 | CA1 (0.41) | LTB4RLTB4R2KMT2AHPGDMEN1 | |
| SCHEMBL28399503 | 0.69 | CES2 (0.44) | MAPTRAB9A | |
| SCHEMBL557120 | 0.68 | NR4A1 (0.38) | NR4A1NR4A2NR4A3MAPTSMN1; SMN2 | |
| SCHEMBL557121 | 0.68 | NR4A1 (0.38) | NR4A1NR4A2NR4A3MAPTSMN1; SMN2 | |
| SCHEMBL28393611 | 0.66 | SMN1; SMN2 (0.45) | KMT2ANR4A1NR4A2NR4A3MAPT | |
| SCHEMBL11438214 | 0.65 | MAOB (0.49) | KMT2AMAPTHPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | STAT3, JAK2, STAT6 | LTB4R 2313/4885LTB4R2 2514/4885ESR1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.